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Relationships between dairy products and cardiovascular risk are debated.
On the one hand, saturated fats contained in dairy products have a deleterious
impact on lipids. On the other hand, dietary calcium has been shown to lower
blood pressure and to be associated with a reduced occurrence of metabolic
syndrome and obesity. 
Aim: To investigate the link between dairy product intake and all-cause
death in a cohort followed over 12 years.
Methods: A sample of 947 men aged 45-64 was randomly selected in
1995-96 from the general population of Lille, Strasbourg and Toulouse areas.
Each participant completed a 3-day food record, checked by a dietician. Vital
status was obtained on December 31, 2009.
Results: Median follow-up was 13.8 years. Cumulative incidence of death
reached 13.3%, with a significant north-south gradient (21.4% in Lille, 10.2%
in Strasbourg, and 7.4% in Toulouse). People who died were significantly
older, had less often graduated from high school, were preferentially farmers,
employees or workers, less often liable to income tax, and more often heavy
smokers or sedentary people. They consumed a lower amount of vegetable
proteins, polysaccharides, polyunsaturated fats, linoleic acid, milk and dairy
products, but a higher amount of alcohol. Compared to people who did not
drink milk, the relative risk of death was 0.64 [(95% CI: 0.42-0.98); p=0.038]
in those consuming up to one glass per day (250 ml) and 0.45 [(0.22-0.94);
p=0.032] for more than one glass, after adjustment for centre, age, high school
completion, job category, liability for income tax, severe chronic disease,
Framingham risk score, alcohol intake, smoking, physical activity, food
quality index, and calorie intake. Other dairy products were not significantly
associated with death.
Conclusion: Drinking milk is associated with a reduced risk of all-cause
death, independently of main confounders such as age, poor diet quality or
health conditions, and educational and socio-economic status. 
313
Probability of significant coronary artery disease in Southern France:
a need for distinctive predictive models
Edouard Cheneau [Orateur] (1), Noemie Resseguier (2), Bruno Vahdat
(1), Philippe Commeau (3), Annamaria Molon (1), Paul Barragan (3),
Pierre Olivier Roquebert (3), Roch Giorgi (2), Dimitri Panagides (1)
(1) Clinique Bouchard, Marseille, France – (2) AP-HM, CHU La Timone,
Santé Publique et d’Information Médicale, Assis, Marseille, France –
(3) Clinique Les Fleurs, Ollioules, France
Background: Likelihood of coronary artery disease (CAD) is based on
predictive models that have been developed in early 70’s in North America.
It’s unknown whether those models are accurate in European populations.
Methods: In two regional centers recruiting urban and peri-urban Southern
French population, patients with suspected CAD were prospectively referred
to Coronary Computed Tomography (CCT) with a 64-slice scan. Inclusion cri-
teria were 1 – clinically suspected angina pectoris or 2 – suspected silent
ischemia on resting EKG. Significant CAD was defined as at least one coro-
nary artery with lumen stenosis >50% by CCT. Likelihood of significant CAD
was estimated using the Duke Model. Predictive quality of the model was
assessed: reliability by comparing the predicted likelihood with the observed
proportion of CAD, and discrimination by comparing the distribution of like-
lihood of significant CAD according to the CAD status and estimating the
c-index of the model. Coefficients associated to the predictive characteristics
presented in the Duke Model were estimated among the included patients.
Results: Out of 824 patients, CCT imaging was adequate in 737 and sig-
nificant CAD was detected in 227 patients (31%). Observed proportion of
patients with significant CAD was lower than the predicted probability
(mainly explained by the change in the expected slope, Graph). Mean pre-
dicted likelihood of significant CAD was 0.48±0.27 and 0.72±0.22 among
patients without and with significant CAD, respectively (p<0.0001). The c-
index was equal to 0.75 (95% CI, 071 to 0.78). Estimates of coefficients of
the characteristics presented in the Duke model varied substantially among our
patients.
Conclusions: The assessment of the quality of predictions of the Duke
model for significant CAD showed an imperfect reliability in our study popu-
lation. Specific predictive models are needed to estimate likelihood of CAD in
Southern France.
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Background: Adiponectin is an hormone secreted by the adipose tissue
that is implied in the regulation of glucose and fatty acids metabolism. We
aimed to investigate in French men with CHD whether plasma adiponectin
levels are associated with long-term mortality, considering varying degrees of
CHD severity.
Methods: Among 834 consecutive men (45-74 years) hospitalized for
CHD between 2001 and 2004, total plasma adiponectin measured by ELISA
and markers of CHD severity (Gensini and Jeopardy scores, resting heart rate
(RHR) and left ventricular dysfunction (LVEF)) were assessed in 736 patients
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aged 60.2±8.0 in average. Mortality was obtained from routine statistics and
median follow-up was 7.2 years. The association of adiponectin with mortality
was determined by a cox proportional hazard model. 
Results: Adiponectin (mean: 5.6±4.3 microg/mL) was significantly associ-
ated (p=0.001) with RHR (mean: 63.8±11.9 beats/mn) and LVEF (median:
55%, p=0.001) but not with the severity of coronary lesions (Gensini and
Jeopardy scores). After multivariable adjustment for age, tobacco consump-
tion, physical activity, history of diabetes, hypertension and dyslipidaemia,
waist girth, ApoA1, length of CHD and severity scores, adiponectin remained
significantly associated with mortality HR: 1.05 (1.01-1.09), p=0.008. In
people with RHR 61.5 beat/mn and LVEF <40% HRs increased significantly
from 2.70 (0.93-7.84) when adiponectin was below median (4.4 microg/mL)
to 7.29 (3.60-14.7) when it was above. The increased risk was similar when
RHR was below 61.5 microg/mL and LVEF below 40%, (from 2.66 (0.73-
9.77) to 6.80 (2.48-18.6)) or in men with RHR 61.5 microg/mL and LVEF
40%, although the strength of the relationship was smaller (from 1.22 (0.59-
2.51) to 2.79 (1.43-5.41)).
Conclusion: High adiponectin levels were associated with long term mor-
tality in French men suffering from CHD after multivariable adjustment. This
prognostic value remains significant whatever the severity of CHD.
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Background: Patients with psoriasis would be exposed to a high risk of
atherosclerosis. This study aimed to assess ten-year cardiovascular risk for
coronary heart disease in Tunisian psoriatic patients and to test the role of pso-
riasis severity and duration on cardiovascular risk.
Methods: A case-control study included 202 psoriatic patients and
216 healthy controls. Risk of coronary heart disease was estimated using the
Framingham risk score algorithm.
Results: Psoriatic patients had higher ten-year Framingham risk score
(12.71±3.81 vs. 7.45±6.66; p<0.001) than controls. Besides, a high risk score
(20% to 40%) was more frequent in psoriatic patients compared with controls
(18.3% vs. 6.5%; p<0.001) and a very high risk (>40%) was noted in 5.9% of
psoriatic patients versus 0% in controls. The cardiovascular risk tend to
increase with severity of psoriasis (10.05±11.22, 14.32±13.97 and
15.46±16.26 for low, high and very high risk levels, respectively). But, no
relationship wad found with duration of psoriasis.
Conclusion: Tunisian psoriatic patients have significantly greater risk of
developing coronary heart disease than controls. The more severe is the pso-
riasis; the higher the risk. Patients with psoriasis should be closely followed
for cardiovascular disease and preventive measures specific interventions
should be initiated according to guidelines in psoriatic patients
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Purpose: Elevated resting heart rate (HR) during the hospitalization for
acute myocardial infarction (MI) is an independent predictor of mortality.
However, there is no study that ascertained HR at early follow-up visit after
the introduction of beta blockers (BB), during the first year after MI. Thus,
our aim was to evaluate the prognostic impact of resting HR at early follow-
up visit after MI in first year survivors, independently of BB use.
Methods: In an MI incident cohort (1983-2007), resting HR at early
follow-up (range 1 to 12 months) after MI was retrieved from an ECG data-
base. First year survivor patients were followed from MI until death or last
follow-up. The patient’s population was divided into 5 categories according to
the HR level. Proportional hazards regression examined the association of HR
with mortality after adjustment for confounders, particularly BB.
Results: The mean follow-up of the 1587 included MI patients in sinus
rhythm (mean age 65±14 years, 62% men) was 9 years with 627 deaths.
Patients with elevated HR had a worse baseline risk profile. Elevated HR at
early follow-up was associated with an increased risk of death (table). In
patients taking or not BB, similar results were obtained (table).
Conclusion: Elevated resting HR at early follow-up visit after MI identi-
fies patients at increased risk of death, independently of BB use. This knowl-
edge may help physicians to identify high-risk subjects easily.
Resting HR at early follow-up (in BPM) in First Year Survivors after MI and 
Death (Adjusted Hazard Ratio (95% CI))*
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Aims: Recommendations of the African Type 2 Diabetes Practice Guide-
line for the use of electrocardiogram in the monitoring of people with diabetes
are non-specific. We assessed the prevalence and determinants of electrocar-
diographic abnormalities in people with diabetes in two referral centers in
Cameroon.
Methods: A total of 420 patients with type 2 diabetes (49% men) receiving
chronic care at the Douala General and Yaounde Central hospitals were
included. Electrocardiographic abnormalities were investigated and related to
potential history, clinical and biological determinants with the use of logistic
regression models.
Results: The mean age and median duration of diagnosed diabetes were
56.7 years and 4 years respectively. The main (prevalence – %) electrocardio-
graphic abnormities were: T waves alterations (20.9%), left ventricular hyper-
trophy according to the Cornell product criteria (16.4%), arrhythmia (16.2%),
ischemic heart disease (13.6%), conduction defects (11.9%), QTc prolongation
(10.2%) and ectopic beats (4.8%). Blood pressure variables (systolic, diastolic
and pulse pressure) were consistently associated with all abnormalities. Dia-
betes specific factors were associated to some, but not all abnormalities.
All 
(n=1587)
BB 
at hospital discharge
(n=1131)
No BB 
at hospital discharge 
(n=456)
HR60 1 1 1
60<HR70 1.5 (1.2-1.9) 1.5 (1.1-2.0) 1.5 (1.0-2.3)
70<HR80 1.6 (1.3-2.1) 1.4 (1.0-1.9) 1.9 (1.2-2.8)
80<HR80 2.1 (1.6-2.7) 1.8 (1.3-2.7) 2.2 (1.4-3.5)
HR>90 2.2 (1.7-2.9) 1.9 (1.3-2.9) 2.5 (1.6-3.9)
*Adjusted for age, sex, body mass index, smoking status, hyperlipidemia, 
hypertension, heart failure, reperfusion/revascularization procedures, 
comorbidity as measured by the Charlson index. Adjustment also for BB at 
discharge in All population.
